Segall Bryant & Hamill LLC Trims Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Segall Bryant & Hamill LLC reduced its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 2.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 56,235 shares of the pharmaceutical company's stock after selling 1,590 shares during the quarter. Segall Bryant & Hamill LLC's holdings in Vertex Pharmaceuticals were worth $22,646,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of the company. Vanguard Group Inc. boosted its position in Vertex Pharmaceuticals by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 23,258,288 shares of the pharmaceutical company's stock valued at $9,366,113,000 after acquiring an additional 98,654 shares during the last quarter. State Street Corp lifted its stake in shares of Vertex Pharmaceuticals by 0.8% in the 3rd quarter. State Street Corp now owns 11,816,249 shares of the pharmaceutical company's stock valued at $5,495,501,000 after purchasing an additional 90,173 shares during the period. Wellington Management Group LLP boosted its position in shares of Vertex Pharmaceuticals by 17.2% during the 3rd quarter. Wellington Management Group LLP now owns 4,798,870 shares of the pharmaceutical company's stock valued at $2,231,858,000 after purchasing an additional 704,421 shares in the last quarter. Janus Henderson Group PLC grew its stake in Vertex Pharmaceuticals by 4.1% during the third quarter. Janus Henderson Group PLC now owns 2,516,831 shares of the pharmaceutical company's stock worth $1,170,506,000 after purchasing an additional 100,114 shares during the period. Finally, Parnassus Investments LLC bought a new stake in Vertex Pharmaceuticals in the fourth quarter worth approximately $731,283,000. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on VRTX shares. Scotiabank increased their price target on Vertex Pharmaceuticals from $433.00 to $450.00 and gave the stock a "sector perform" rating in a report on Tuesday, February 11th. Canaccord Genuity Group raised shares of Vertex Pharmaceuticals from a "sell" rating to a "hold" rating and increased their target price for the stock from $408.00 to $424.00 in a research note on Tuesday, February 11th. Bank of America decreased their price target on shares of Vertex Pharmaceuticals from $545.00 to $522.00 and set a "buy" rating for the company in a research note on Thursday, December 19th. StockNews.com raised shares of Vertex Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Tuesday, March 11th. Finally, Wells Fargo & Company lowered Vertex Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $460.00 target price for the company. in a research report on Thursday, January 30th. Ten research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Vertex Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $506.70.

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 244 shares of the business's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $455.06, for a total value of $111,034.64. Following the sale, the executive vice president now directly owns 67,695 shares in the company, valued at $30,805,286.70. The trade was a 0.36 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP David Altshuler sold 3,231 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $500.00, for a total value of $1,615,500.00. Following the transaction, the executive vice president now owns 26,512 shares of the company's stock, valued at $13,256,000. The trade was a 10.86 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 4,315 shares of company stock worth $2,121,012 over the last three months. 0.20% of the stock is currently owned by insiders.

Vertex Pharmaceuticals Stock Performance

Vertex Pharmaceuticals stock traded down $5.83 during mid-day trading on Friday, reaching $496.72. 378,702 shares of the company's stock were exchanged, compared to its average volume of 1,271,287. The firm has a market capitalization of $127.55 billion, a PE ratio of -226.01, a P/E/G ratio of 2.11 and a beta of 0.41. The company has a quick ratio of 2.35, a current ratio of 2.69 and a debt-to-equity ratio of 0.01. The business's fifty day simple moving average is $475.04 and its 200 day simple moving average is $463.61. Vertex Pharmaceuticals Incorporated has a one year low of $377.85 and a one year high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 EPS for the quarter, missing analysts' consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. On average, sell-side analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.